In Brief: Candela's GentleLASE
This article was originally published in The Gray Sheet
Executive Summary
Candela's GentleLASE: FDA clears the long-pulse alexandrite laser product for treatment of vascular lesions. Wayland, Massachusetts-based Candela says it will launch GentleLASE at a price of $59,500, "which is 50-60% lower than that of any competitive systems," with the price remaining in effect through the March 4 end of the American Academy of Dermatology meeting. Shipments are expected to begin during the first quarter of 1998...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.